Global Health Research Interests: Clinical Trials, Community Health, COVID, Global Health Policy, Global Health Systems/Delivery, Health Policy, HIV/AIDS, Infectious Diseases, Public Health, Tuberculosis (TB)

Countries: Ghana, Mozambique, South Africa, United States

Prof Churchyard (MBBCh), MMED (Int Med), FCP (SA), FRCP (Edin), PhD) is a specialist physician internationally renowned for his contributions to tuberculosis (TB) research. Prof Churchyard is the founder and Group Chief Executive Officer of the Aurum Institute, an independent, not-for-profit, proudly South African, public benefit organization focusing on TB and HIV technical assistance, service delivery, and research. Prof Churchyard is an Honorary Professor at the University of Witwatersrand, the University of Cape Town, and the Department of Medicine at the Vanderbilt University School of Medicine. Prof Churchyard is the Chair of the AIDS Clinical Trials Group (ACTG) Transformative Science Group for TB, Chair of the NIH/DIADS funded Cross-network TB vaccine and Immunology Working Group, and a member of the ACTG Scientific Advisory Steering Committee (SASC). He has extensive clinical trial experience and has conducted numerous TB treatments, TB vaccines, TB preventive therapies, TB diagnostics, and Host Directed Therapy for TB trials. Prof Churchyard's investigator-initiated studies have involved large, multisite, and often complex studies in South Africa and internationally. Prof Churchyard has published widely in the fields of TB and HIV.

The Aurum Institute
Parktown, South Africa

Global Health Research Interests: HIV/AIDS, Tuberculosis (TB)

Country: Mozambique

The Aurum Institute
Parktown, South Africa

Ms. Tanya Nielson has been involved in clinical trials for more than 12 years and has been in a management role for a decade. These include HIV Prevention Vaccine, HIV Therapeutic Vaccine, TB vaccine, TB drug, HIV prevention PrEP/Microbicide and contraception trials and several observational studies.

The Aurum Institute
Parktown, South Africa

Global Health Research Interests: Clinical Trials, HIV/AIDS, Mobile Health, Public Health, Technical Assistance Service (PEPFAR), Trauma and Injury, Tuberculosis, Executive Leadership and Governance

Countries: Bangladesh, Burkina Faso, Congo (the Democratic Republic of the), Eswatini, Ethiopia, Gambia (the), Georgia, Ghana, Haiti, India, Indonesia, Kenya, Lesotho, Malawi, Maldives, Moldova (the Republic of), Mozambique, Nigeria, Pakistan, South Africa, Switzerland, Tanzania, Uganda, Zambia, Zimbabwe

Adjunct Professor Dave Clark is the Group Chief Executive Officer (CEO) and an executive director and board member of The Aurum Institute. He is also an Adjunct Professor at the Department of Medicine in the Vanderbilt University School of Medicine. He is strongly involved in the health programmes, corporate services and strategic leadership of the company. His activities include oversight of the financial, human resource and data management services to support the work of the scientific and clinical departments.

Education

MBBCh, DHSM, University of Witwatersrand, South Africa
MBA, University of Potchefstroom, South Africa

Global Health Research Interests: Clinical Trials, COVID, Epidemiology, HIV/AIDS, Tuberculosis (TB), Vaccinology

Country: South Africa

The Aurum Institute
Parktown, South Africa

Education

MBChB, University Of Pretoria
MSc, London School of Hygiene and Tropical Medicine

Global Health Research Interests: Clinical Pharmacology, Clinical Trials, Immunology, Infectious Diseases, Pharmacology, Pulmonary Medicine/ Respiratory Care, Tuberculosis (TB), Vaccinology

Countries: Georgia, Germany, India, Moldova, Mozambique, Romania, South Africa

Dr Wallis is the Chief Scientific Officer: Host Directed Therapy and is an an Adjunct Professor at the Department of Medicine in the Vanderbilt University School of Medicine. He holds adjunct appointments as Professor at Case Western Reserve University and Rutgers-New Jersey Medical School, where he previously held full-time positions. He has published approximately 140 manuscripts*, review articles, and book chapters, mainly in the areas of tuberculosis biomarkers, immunotherapy, and anti-infective drug development. He has particular expertise in the use of innovative models to evaluate new drugs and vaccines.

Professor Wallis came to Aurum after nearly 10 years in the pharmaceutical industry, most recently at Pfizer, where his leadership in anti-infective R&D included the TB candidate sutezolid**. He is a member of the editorial board of the Journal of Infectious Diseases and is a Fellow of the Infectious Diseases Society of America and the Royal College of Physicians of Edinburgh. Dr Wallis is presently leading multiple studies of adjunctive host-directed therapies in tuberculosis at Aurum.

Global Health Research Interests: Epidemiology, HIV/AIDS, Implementation Science, Infectious Diseases, Tuberculosis

Countries: Brazil, Cambodia, Ethiopia, Ghana, India, Indonesia, Kenya, Malawi, Mozambique, South Africa, Zimbabwe

Prof. Chihota is The Group Chief Scientific Officer at The Aurum Institute. She has over 20 years' experience in global health, in the fields of TB and TB/HIV co-infection. Her work has focused on the molecular epidemiology of drug sensitive- and resistant-TB, diagnosis of tuberculosis and linkage into care post diagnosis. Her current interests are in understanding resistance to TB infection and evaluating strategies to prevent tuberculosis in people with TB/HIV coinfection.

The Aurum Institute
Parktown, South Africa